Prime Medicine (PRME) announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock in the proposed offering are to be sold by Prime Medicine. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. TD Cowen and BMO Capital Markets are acting as joint book-running managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Largest borrow rate increases among liquid names
- Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic Advancements
- Prime Medicine announces additional funding of up to $24M from CF Foundation
- Prime Medicine Announces CSO Resignation and Transition
- JonesResearch lists factors for Prime Medicine continued share rally